+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biologics Outsourcing Global Market - Forecast to 2028

  • ID: 5150034
  • Report
  • October 2020
  • Region: Global
  • 633 Pages
  • IQ4I Research & Consultancy Pvt. Ltd

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • Batavia Biosciences B.V.
  • Cytovance Biologics
  • JHL biotech Inc.
  • Northway BiotechPharma
  • Sino Biological Inc.
  • MORE

The biologics outsourcing global market is expected to grow at low teen CAGR to reach $87.5 billion by 2028. Biologics are the therapeutic entities composed of sugars, proteins, or nucleic acids and made from natural sources such as human, animal or microorganisms. Biologics also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (for transplantation), cell and gene therapeutics. Similar to the conventional therapeutics, these drugs help in treating several diseases but are highly specific and more efficient in their disease healing mechanisms. The biologic entities like monoclonal antibodies and recombinant proteins target specific areas during their molecular mechanism of disease curing.

Even though biologics are highly expensive when compared to the conventional small molecule drugs, these target specific therapeutics have proven to be very beneficial for patients and also ensure higher profit margins to the drug manufacturers. The escalating adoption of biologics and elevating demand for the highly efficient biotherapeutics from the value-centric patient population across the globe, increasing investments on research and developmental activities of biologics and advanced, next-generation biotherapeutics, a favorable and streamlined regulatory environment that is expediting the novel product approval process and the expansion of biosimilar market have all led to the rapid growth of the biopharmaceutical market. Due to the increasing demand for biologics drugs and increased regulatory approvals for these drugs, there is huge demand for biologics manufacture and testing at various levels of clinical studies as well as commercial supply.

This fast pacing biologic industry coupled with insufficient or lack of in house biologic development and manufacturing capabilities and capacities of biopharmaceutical companies has spurred these companies to outsource the different parts of biologic development and manufacturing process to highly efficient service providing organizations. The Large Biopharma companies are coming up with strategies to cut down on their operational costs and concentrate more on their core competencies by outsourcing this piece of work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These organizations bridge the gap between demand and supply and ensure the drug discovery and manufacturing process gets much faster and convenient; thus bringing the life-saving drugs to the market and the needy patients at the earliest.

In 2019, seven out of the 10 blockbuster drugs were biologics, outnumbering small molecule drugs. Some of the top-selling biologics in 2019 include Humira ($19.1 billion), Keytruda ($11.0 billion), Avastin ($7.28 billion) and Opdivo ($7.20 billion). The growth of biologics market indirectly indicates the huge demand for services spanning all stages of biologic development starting from the preclinical stage to commercial manufacturing. The high complexity associated with development and manufacturing of biologics and requirement of specialized equipments and skills for biomanufacturing is prompting the biopharma companies to turn to outsourcing as a viable option. Thus the CMO’s offering quality compliant, rapid bioproduction and supply services, scalable and flexible capacities with stable capabilities at competitive costs will become an integral part of the biopharmaceutical company.

Various stages of biological development require different types of services as listed below.

  • Discovery services- Includes lead identification and validation for identifying possible drug candidates targeting specific diseases. The process further involves steps such as target validation, screening preparation, hit generation and lead selection, lead optimization and characterization and finally lead selection.
  • Preclinical development services- Involves in-vitro and in-vivo studies of the biologic drug candidates before testing them on humans to test the safety, efficacy and biological functionality against the disease target. Preclinical services include cell line engineering, process development, product analytical characterization, cGMP cell banking, cell line characterization, animal model assay development and testing services.
  • Clinical development- Clinical development includes testing potential drug candidates on humans in phase I, II and II trials. Services at this stage include cGMP grade clinical supply of biologics such as MAb, or recombinant protein, stability testing, fill/finish and regulatory support.

Commercialization- Once the drug has passed all the necessary approvals, the manufacture, marketing and sale of commercial quantities is performed. Outsourcing partners here manufacture the commercial supply for product launch and sale.

The biologics outsourcing global market has been segmented based on the developmental phase, product, end users and geography. Among the discovery, pre-clinical, clinical and commercial phases of biologics development, Commercial Phase outsourcing commanded the largest revenue in 2020. It is also the fastest growing segment and is expected to grow at low teen CAGR during the forecasted period. The biological outsourcing market by product type is segmented into Antibody, Proteins, Vaccines, Gene therapy, cell therapy and others. Among these, the antibody outsourcing segment accounted for the largest share of revenue in 2020 and is expected to grow at low teen CAGR during the forecasted period. Gene therapeutics segment is expected to be the fastest emerging market growing at low teen CAGR during the forecasted period. Based on end – users, the biologics outsourcing market is segmented into Therapeutics, Diagnostics and Research. Therapeutics is the largest and fastest growing segment and is expected to grow at low teen CAGR from 2020 to 2028. Geographically, North America dominated the biologics outsourcing market with the highest revenue in 2020 and is expected to grow at double digit CAGR from 2020 to 2028. Asia Pacific region is expected to be the fastest emerging market growing at mid teen CAGR during the forecasted period.

The report specifically emphasizes on the rapidly evolving and high growth potential biologics contract manufacturing services market and cell line development services market. Biologics contract biomanufacturing services global market is expected to reach $57.1 billion by 2028 growing at a low teen CAGR from 2020 to 2028. The cell line development service global market is expected to reach $1,702.2 million by 2028 growing at a double digit CAGR from 2020 to 2028.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • Batavia Biosciences B.V.
  • Cytovance Biologics
  • JHL biotech Inc.
  • Northway BiotechPharma
  • Sino Biological Inc.
  • MORE

1 Biologics Outsourcing Global Market
1.1 Introduction
1.2 Landscape of Biologics Market
1.3 Rise of Biosimilars
1.4 Biosimilars Global Market, by Region
1.5 Biologics Global Market
1.6 Top Destination for Biologics Outsourcing
1.6.1 China Biologics Outsourcing Market
1.6.2 India Biologics Outsourcing Market
1.6.3 China Vs India - Biologics Market
1.6.4 Regulations and Government Initiatives
1.6.5 Capabilities and Technologies

2 Market Analysis
2.1 Introduction
2.2 Factors Influencing Market
2.2.1 Drivers and Opportunities
2.2.1.1 Increasing Trend of Outsourcing
2.2.1.2 Advanced Bioprocessing Capabilities of Bioservice Providers
2.2.1.3 Emergence of Next Generation Biologics
2.2.1.4 Escalating Approvals and Uptake of Biosimilars
2.2.1.5 Increasing Approvals and Adoption of Biologics
2.2.1.6 Increasing R&D Expenditures
2.2.1.7 Increasing Prevalence of Chronic, Communicable and Autoimmune Diseases
2.2.1.8 Development of Personalized and Orphan Indication Therapies
2.2.2 Restraints and Threats
2.2.2.1 Increasing Focus on In-House Biologics Manufacturing
2.2.2.2 Huge Capital Investments for Capacity and Capability Development
2.2.2.3 Compliance With Stringent Regulatory Guidelines
2.2.2.4 Concerns About Ip Protection
1.2.2.5 Competition and Trend of Outsourcing of Low Volume Biologics

3 Biologics Outsourcing Global Market, Market Analysis
3.1 Introduction
3.2 Discovery and Pre-Clinical Development Process
3.3 Biologics Outsourcing Global Market, by Product Type
3.3.1 Antibody
3.3.1.1 Monoclonal Antibody
3.3.1.2 Bispecific Antibody
3.3.1.3 Antibody Drug Conjugates
3.3.1.4 Others (Polyclonal Antibody, Antibody Fragments)
3.3.2 Recombinant Protein
3.3.3 Fusion Proteins
3.3.3.1 Hormones
3.3.3.2 Recombinant Enzymes
3.3.3.3 Others (Cytokines, Peptides)
3.3.4 Vaccines
3.3.5 Gene Therapy
3.3.6 Cell Therapy
3.3.6.1 Others (Transgenic Proteins and Other Recombinant Products)
3.4 Biologics Outsourcing Global Market, by Endusers
3.4.1 Therapeutics
3.4.2 Diagnostics
3.4.3 Research
3.5 Bioanalytical Testing Services
3.6 Market Share Analysis
3.7 Company Developments
3.7.1 Agreement, Collaborations and Partnerships
3.7.2 Expansion
3.7.3 Product, Technolgy and Service Launch
3.7.4 Acquisitions
3.7.5 Other Developments
3.8 Service Cost Analysis
3.8.1 Antibody Production Service Costs
3.8.2 Custom Monoclonal Antibody Production Service Costs
3.8.3 Custom Polyclonal Antibody Production Service Costs
3.8.4 Protein Production Service Costs
3.8.5 Additional Antibody and Protein Services
3.8.6 Gene Editting Services
3.8.7 Car-T/Nk Platform Services

4 Biologics Outsourcing Global Market - Biomanufacturing
4.1 Introduction
4.2 Market Dynamics
4.3 in House Vs Cmo Capacity
4.3.1 Global Biomanufacturing Capacity
4.3.2 Biologics Contract Manufacturing Organizations, by Phase
4.4 Contract Biomanufacturing, by Process
4.4.1 Biomanufacturing by Mammalian Cell Culture
4.4.2 Mammalian Cell Culture Biomanufacturing V/S Microbial and Other Cell Cultures
4.4.3 Biomanufacturing by Microbial Cell Culture
4.4.3.1 Microbial Cell Culture Cmo Biomanufacturing Capacity
4.4.4 Biomanufacturing by Other Cell Culture
4.5 Contract Biomanufacturing Global Market, by End-users
4.5.1 Contract Biomanufacturing of Diagnostics
4.5.2 Contract Biomanufacturing of Research Reagents
4.5.3 Contract Biomanufacturing of Therapeutics
4.5.3.1 Biomanufacturing of Antibodies
4.5.3.2 Biomanufacturing of Recombinant Proteins
4.5.3.3 Biomanufacturing of Vaccines
4.5.3.4 Other Biologics Contract Biomanufacturing
4.6 Biomanufacturing Outsourcing Global Market, by Region
4.7 Contract Biomanufacturing Capacity Penetration
4.8 Competitive Landscape
4.8.1 Capacity Comparison
4.8.2 Contract Manufacturing Global Market Share, by Leading Players
4.8.3 Company Developments
4.8.3.1 Agreement
4.8.3.2 Expansion
4.8.3.3 Acquisition
4.8.3.4 Collaboration and Partnerships
4.8.3.5 Product Launch
4.8.3.6 Facility Approvals
4.8.3.7 Other Developments

5 Biologics Outsourcing Global Market - Cell Line Development
5.1 Introduction
5.1.1 Market Dynamics
5.2 Cell Line Development
5.2.1 Cell Line Construction
5.2.2 Host Cell Line Engineering
5.2.3 Expression System
5.2.4 Transient Gene Expression
5.2.5 Stable Cell Line Development
5.2.6 Screening
5.2.7 Upstream Process Development
5.3 Host Cell Lines
5.4 Cell Line Development Services Market, by Expression System
5.4.1 Microbial Expression Systems
5.4.2 Mammalian Expression System
5.4.3 Others (Insect and Plant Cell)
5.5 Cell Line Development Services, by Cell Type
5.5.1 Cho
5.5.2 Murine/Mouse Myeloma
5.5.3 Baby Hamster Kidney (Bhk) Cells
5.5.4 Hybridoma
5.5.5 Human Embryonic Kidney (Hek) Cells
5.5.6 Human Embryonic Retinal Cells (Per.C6)
5.5.7 Others (E.Coli, Yeast, Insect Cell, Ht-1080, Hela Cell Line, Cap, Hkb-11, Huh-7)
5.6 Cell Line Development Services, by Applications
5.6.1 Research
5.6.2 Bioproduction
5.6.3 Diagnostics
5.7 Cell Banking Services
5.8 Cell Line Characterization Services
5.9 Market Share Analysis
5.10 Key Developments
5.10.1 Agreements
5.10.2 New Technology, Product and Service Launch
5.10.3 Expansion
5.10.4 Other Developments

6 Company Profiles
6.1 Abbvie Inc.
6.1.1 Overview
6.1.2 Financials
6.1.3 Service Portfolio
6.1.4 Key Developments
6.1.5 SWOT Analysis
6.2 Abzena plc
6.2.1 Overview
6.2.2 Financials
6.2.3 Service Portfolio
6.2.4 Key Developments
6.2.5 SWOT Analysis
6.3 AGC Inc.
6.3.1 Overview
6.3.2 Financials
6.3.3 Service Portfolio
6.3.4 Key Developments
6.3.5 SWOT Analysis
6.4 Albany Molecular Research, Inc.
6.4.1 Overview
6.4.2 Financials
6.4.3 Service Portfolio
6.4.4 Key Developments
6.4.5 SWOT Analysis
6.5 Boehringer Ingelheim International GmbH
6.5.1 Overview
6.5.2 Financials
6.5.3 Service Portfolio
6.5.4 Key Developments
6.5.5 SWOT Analysis
6.6 Catalent Inc.
6.6.1 Overview
6.6.2 Financials
6.6.3 Service Portfolio
6.6.4 Key Developments
6.6.5 SWOT Analysis
6.7 Charles River Laboratories
6.7.1 Overview
6.7.2 Financials
6.7.3 Service Portfolio
6.7.4 Key Developments
6.7.5 SWOT Analysis
6.8 Cognate Bioservices Inc. (Cobra Biologics)
6.8.1 Overview
6.8.2 Financials
6.8.3 Service Portfolio
6.8.4 Key Developments
6.8.5 SWOT Analysis
6.9 Envigo
6.9.1 Overview
6.9.2 Financials
6.9.3 Service Portfolio
6.9.4 Key Developments
6.9.5 SWOT Analysis
6.10 Eurofins Scientific S.E.
6.10.1 Overview
6.10.2 Financials
6.10.3 Service Portfolio
6.10.4 Key Developments
6.10.5 SWOT Analysis
6.11 Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnol0Gies)
6.11.1 Overview
6.11.2 Financials
6.11.3 Service Portfolio
6.11.4 Key Developments
6.11.5 SWOT Analysis
6.12 Genscript Biotech Corporation
6.12.1 Overview
6.12.2 Financials
6.12.3 Service Portfolio
6.12.4 Key Developments
6.12.5 SWOT Analysis
6.13 Intertek Group plc
6.13.1 Overview
6.13.2 Financials
6.13.3 Service Portfolio
6.13.4 Key Developments
6.13.5 SWOT Analysis
6.14 Iqvia Holdings Inc.
6.14.1 Overview
6.14.2 Financials
6.14.3 Service Portfolio
6.14.4 Key Developments
6.14.5 SWOT Analysis
6.15 JSR Corporation
6.15.1 Overview
6.15.2 Financials
6.15.3 Service Portfolio
6.15.4 Key Developments
6.15.5 SWOT Analysis
6.16 Laboratory Corp of America Holdings
6.16.1 Overview
6.16.2 Financials
6.16.3 Service Portfolio
6.16.4 Key Developments
6.16.5 SWOT Analysis
6.17 Lonza Group Ltd.
6.17.1 Overview
6.17.2 Financials
6.17.3 Service Portfolio
6.17.4 Key Developments
6.17.5 SWOT Analysis
6.18 Merck Kga
6.18.1 Overview
6.18.2 Financials
6.18.3 Product Portfolio
6.18.4 Key Developments
6.18.5 SWOT Analysis
6.19 Rentschler Biopharma Se
6.19.1 Overview
6.19.2 Financials
6.19.3 Service Portfolio
6.19.4 Key Developments
6.19.5 SWOT Analysis
6.20 Samsung Biologics Co. Ltd.
6.20.1 Overview
6.20.2 Financials
6.20.3 Service Portfolio
6.20.4 Key Developments
6.20.5 SWOT Analysis
6.21 Sartorius Group
6.21.1 Overview
6.21.2 Financials
6.21.3 Service Portfolio
6.21.4 Key Developments
6.21.5 SWOT Analysis
6.22 SGS Sa
6.22.1 Overview
6.22.2 Financials
6.22.3 Service Portfolio
6.22.4 Key Developments
6.22.5 SWOT Analysis
6.23 Syngene International Ltd.
6.23.1 Overview
6.23.2 Financials
6.23.3 Service Portfolio
6.23.4 Key Developments
6.23.5 SWOT Analysis
6.24 Thermo Fisher Scientific Inc.
6.24.1 Overview
6.24.2 Financials
6.24.3 Service Portfolio
6.24.4 Key Developments
6.24.5 SWOT Analysis
6.25 Wuxi Apptec Co. Ltd.
6.25.1 Overview
6.25.2 Financials
6.25.3 Service Portfolio
6.25.4 Key Developments
6.25.5 SWOT Analysis
6.26 Wuxi Biologics (Cayman) Inc.
6.26.1 Overview
6.26.2 Financials
6.26.3 Service Portfolio
6.26.4 Key Developments
6.26.5 SWOT Analysis

List of Tables
Table 1 Patent Expiry of Biologics (2018 – 2030)
Table 2 Biosimilars Global Market, by Region, (2019-2028) ($Bn)
Table 3 Highlights of the Revised Guidelines
Table 4 Biologics Outsourcing Global Market Revenue, by Region (2019-2028) ($Bn)
Table 5 Biologics Outsourcing Global Market Revenue, by Product (2019-2028) ($Bn)
Table 6 List of Biologics Approved (2014-2020*)
Table 7 Biologics Outsourcing Global Market Revenue, by Phase (2019-2028) ($Bn)
Table 8 Antibody Outsourcing Global Market Revenue, by Product Type (2019-2028) ($Bn)
Table 9 Biologics Outsourcing Global Market Revenue, by End-users (2019-2028) ($Bn)
Table 10 Agreement, Collaborations and Partnerships (2019 -2020)
Table 11 Expansions (2019-2020)
Table 12 Product, Technology and Service Launch (2019-2020)
Table 13 Acquisitions (2019-2020)
Table 14 Other Developments (2019 – 2020)
Table 15 Service Comparison Matrix of the Company Based on Biologics Type
Table 16 Capacity Comparison of Contract Manufacturing Organizations V’S In-House Capacities (L)
Table 17 Biologics Manufactured in Mammalian Cell Culture
Table 18 Contract Manufacturing Organizations Capacity, by Process (L)
Table 19 Biologics Manufactured in Microbial Cell Culture
Table 20 Biomanufacturing Outsourcing Global Market by End-users, (2019-2028) ($Bn)
Table 21 Selected Fda Approved Therapeutic Peptides and Proteins
Table 22 Biomanufacturing Outsourcing Global Market by Region, (2019-2028) ($Bn)
Table 23 Agreement
Table 24 Expansion
Table 25 Acquisition
Table 26 Collaboration and Partnerships
Table 27 Product Launch
Table 28 Facility Approvals
Table 29 Other Developments
Table 30 Company Comparison Matrix, by Manufacturing Capability
Table 31 Cell Line Development Services Market, by Region, (2019-2028) ($Mn)
Table 32 Approved Biologics and Cell Line Type (2014-2020)
Table 33 Number of Approved Biologics by Cell Line Type (2014-2020)
Table 34 Cell Line Development Services Market, by Expression System, (2019-2028) ($Mn)
Table 35 Cell Line Development Services Market, by Cell Type, (2019-2028) ($Mn)
Table 36 Cell Line Type of Some Approved Biologics Modalities and Cell Line Type
Table 37 Cell Line Development Services Market, by Application, (2019-2028) ($Mn)
Table 38 Cell Line Development Technologies
Table 39 Cell Line Development Services Cost
Table 40 Agreements (2019 -2020)
Table 41 New Technology, Product and Service Launch (2019-2020)
Table 42 Expansions (2019-2020)
Table 43 Others (2019-2020)
Table 44 Comparison Matrix of Cell Line Development Players and Services Offered
Table 45 Abbvie Inc.: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 46 Abbvie Inc.: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 47 Abbvie Inc.: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 48 AGC Inc.: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 49 AGC Inc.: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 50 AGC Inc.: Chemicals Revenue, by Sub-Segments, (2018-2020) ($Mn)
Table 51 AGC Inc.: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 52 Boehringer Ingelheim: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 53 Boehringer Ingelheim: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 54 Boehringer Ingelheim: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 55 Catalent Inc: Total Revenue and R&D Expenses (2018-2020) ($Mn)
Table 56 Catalent Inc: Total Revenue, by Segment, (2018-2020) ($Mn)
Table 57 Charles River Laboratories: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 58 Charles River Laboratories: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 59 Charles River Laboratories: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 60 Eurofins Scientific S.E. : Total Revenue and R&D Expenses (2018-2020) ($Mn)
Table 61 Eurofins Scientific S.E : Total Revenue, by Geography, (2018-2020) ($Mn)
Table 62 Fujifilm Holdings Corporation: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 63 Fujifilm Holdings Corporation: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 64 Fujifilm Holding Corporation: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 65 Genscript Biotech Corporation: Total Revenue and R&D Expenses, (2017-2019) ($Mn)
Table 66 Genscript Biotech Corporation: Total Revenue, by Segments, (2017-2019) ($Mn)
Table 67 Genscript Biotech Corporation: Total Revenue, by Geography, (2017-2019) ($Mn)
Table 68 Intertek Group plc.: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 69 Intertek Group plc.: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 70 Intertek Group plc.: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 71 Iqvia Holdings Inc.: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 72 Iqvia Holdings Inc.: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 73 Iqvia Holdings Inc.: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 74 JSR Corporation: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 75 JSR Corporation: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 76 JSR Corporation: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 77 Laboratory Corporation: Total Revenue and R&D Expenses (2018-2020) ($Mn)
Table 78 Laboratory Corporation: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 79 Laboratory Corporation: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 80 Lonza Group: Total Revenue & R&D Expenses (2018 -2020) ($Mn)
Table 81 Lonza Group: Total Revenue, by Segment, (2018-2020) ($Mn)
Table 82 Lonza Group: Total Revenue, by Geography (2018-2020) ($Mn)
Table 83 Merck Kga: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 84 Merck Kga: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 85 Merck Kga: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 86 Samsung Biologics Co: Total Revenue (2018-2020) ($Mn)
Table 87 Samsung Biologics: Total Revenue, by Geography (2018-2020) ($Mn)
Table 88 Samsung Biologics: Contract Manufacturing Revenue, by Type (2018-2020) ($Mn)
Table 89 Sartorius : Total Revenue and R&D Expenses (2018-2020) ($Mn)
Table 90 Sartorius: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 91 Sartorius: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 92 SGS Sa: Total Revenue & R&D Expenses (2018-2020) ($Mn)
Table 93 SGS Sa: Total Revenue, by Segment, (2018-2020) ($Mn)
Table 94 SGS Sa: Total Revenue, by Geography (2018-2020) ($Mn)
Table 95 Syngene International: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 96 Syngene International: Total Revenue, by Operations, (2018-2020) ($Mn)
Table 97 Thermo Fisher Scientific Inc.: Total Revenue and R&D Expenses (2018-2020) ($Mn)
Table 98 Thermo Fisher Scientific Inc.: Total Revenue, by Segment, (2018-2020) ($Mn)
Table 99 Thermo Fisher Scientific Inc.: Total Revenue, by Product Type, (2018-2020) ($Mn)
Table 100 Thermo Fisher Scientific Inc.: Total Revenue, by Geography (2018-2020) ($Mn)
Table 101 Wuxi Apptec Co. Ltd.: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 102 Wuxi Apptec Co. Ltd.: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 103 Wuxi Apptec Co. Ltd.: Total Revenue, by Geography, (2018-2020) ($Mn)
Table 104 Wuxi Biologics: Total Revenue and R&D Expenses, (2018-2020) ($Mn)
Table 105 Wuxi Biologics: Total Revenue, by Segments, (2018-2020) ($Mn)
Table 106 Wuxi Biologics: Total Revenue, by Geography, (2018-2020) ($Mn)

List of Figures
Figure 1 Top Selling Drugs (2015 – 2019), Small Molecules V/S Biologics, (2012-2020)
Figure 2 Top 30 Biologics Patent Expiry, (2020-2032) and Rise of Biosimilars
Figure 3 Biologics Revenue Generation in Non-Traditional Therapies (2018 Vs 2019)
Figure 4 Outlook of Biologics Global Market (2019-2028) ($Bn)
Figure 5 Outlook of China Biologics and Biologics Outsourcing Market (2019-2028) ($Bn)
Figure 6 Outlook of India Biologics and Biologics Outsourcing Market (2019-2028) ($Bn)
Figure 7 China Vs India
Figure 8 Market Dynamics
Figure 9 Biologics Outsourcing Global Market Revenue, by Region (2019-2028) ($Bn)
Figure 10 Biologics Outsourcing Global Market Share, by Product, (2020 V/S 2028) (%)
Figure 11 Discovery Biologics Outsourcing Market Share, by Services 2020 (%)
Figure 12 Discovery Biologics Outsourcing Market, by Service Type, 2020 ($Mn)
Figure 13 Biologics Outsourcing Global Market Revenue, by Phase (2020 V/S 2028) ($Bn)
Figure 14 Antibody Outsourcing Global Market Revenue, by Product Type, (2020 V/S 2028) ($Bn)
Figure 15 Biologics Outsourcing Global Market Revenue, by End-Users (2020 V/S 2028) ($Bn)
Figure 16 Biologics Outsourcing Global Market Share Analysis, by Major Players, 2020 (%)
Figure 17 Key Deals (2019-2020)
Figure 18 Market Dynamics of Contract Biomanufacturing Global Market
Figure 19 Global Manufacturing Capacity, Cgmp V’S Non-Cgmp, Inhouse V’S Cmo, 2019-2028
Figure 20 Capacity Utilization of Contract Manufacturing Organizations, by Stage (Million Liters) (2018-2028)
Figure 21 Biologics Cmo Global Market, by Phase, (2018-2028) ($Bn)
Figure 22 Biologics Cmo Global Market, by Process, (2018-2028) ($Bn)
Figure 23 Global Capacity Comparison of Mammalian, Microbial and Other Culture Systems (Mn L) (2018-2028)
Figure 24 Cmo Capacity Comparison of Mammalian, Microbial and Other Culture Systems (Mn L) (2018-2028)
Figure 25 Bio-Manufacturing Outsourcing Global Market, by End-users, (2019-2028) ($Bn)
Figure 26 Adc Pipeline for Cancer (2020)
Figure 27 Monoclonal Antibody Pipeline for Non-Cancer Indications (2020)
Figure 28 Monoclonal Antibody Pipeline for Cancer (2020)
Figure 29 Outlook of Biologics Cmo Global Market Share, by Region 2020 (%) and Manufacturing in Metric Tons, (2019-208)
Figure 30 Contract Biomanufacturing Capacity Penetration (2020)
Figure 31 Capacity Comparison of Top 15 Contract Manufacturing Organizations (L)
Figure 32 Contract Manufacturing Global Market Share, by Leading Players, 2020 (%)
Figure 33 Key Deals (2019 – 2020)
Figure 34 Market Dynamics of Cell Line Development
Figure 35 Cell Line Development Services Market, by Region, (2020 Vs 2028) (%)
Figure 36 Number of Approved Biologics by Cell Line Type (2014-2019)
Figure 37 Cell Line Development Services Market, by Expression System, (2020 V/S 2028) ($Mn)
Figure 38 Expression Systems of Some Approved Biologics (2014 – 2020)
Figure 39 Cell Line Development Services Market, by Cell Type, (2020 V/S 2028) ($Mn)
Figure 40 Cell Line Type of Some Approved Biologics (No’S)
Figure 41 Cell Line Type of Some Approved Biologics Modalities and Cell Line Type
Figure 42 Cell Line Development Services Market, by Application, (2020 V/S 2028) ($Mn)
Figure 43 Cell Line Development Servcies Global Market Share, by Leading Players (2020) (%)
Figure 44 Key Developments of Cell Line Development Market Players, 2019-2020
Figure 45 Overview: Abbvie Inc.
Figure 46 SWOT: Abbvie Inc.
Figure 47 SWOT: Abzena plc
Figure 48 Overview: AGC Inc.
Figure 49 SWOT: AGC Inc.
Figure 50 SWOT: Albany Molecular Research, Inc.
Figure 51 Overview: Boehringer Ingelheim
Figure 52 SWOT: Boehringer Ingelheim
Figure 53 Overview: Catalent Inc.
Figure 54 SWOT: Catalent Inc.
Figure 55 Overview: Charles River Laboratories
Figure 56 SWOT: Charles River Laboratories
Figure 57 SWOT: Cognate Bioservices Inc.
Figure 58 SWOT: Envigo
Figure 59 Overview: Eurofins Scientific
Figure 60 SWOT: Eurofins Scientific
Figure 61 Overview: Fujifilm Holding Corporation
Figure 62 SWOT: Fujifilm Holding Corporation
Figure 63 Overview: Genscript Biotech Corporation
Figure 64 SWOT: Genscript Biosciences Corporation
Figure 65 Overview: Intertek Group plc.
Figure 66 SWOT: Intertek Group plc.
Figure 67 Overview: Iqvia Holdings Inc.
Figure 68 SWOT: Iqvia Holdings Inc.
Figure 69 Overview: JSR Corporation
Figure 70 SWOT: JSR Corporation
Figure 71 Overview: Laboratory Corp of America Holdings
Figure 72 SWOT: Laboratory Corporation of America Holdings
Figure 73 Overview: Lonza Group
Figure 74 SWOT: Lonza Group
Figure 75 Overview: Merck Kga
Figure 76 SWOT: Merck Kgaa
Figure 77 SWOT: Rentschler Biopharma
Figure 78 Overview: Samsung Biologics
Figure 79 SWOT: Samsung Biologics
Figure 80 Overview: Sartorius
Figure 81 SWOT: Sartorius Group
Figure 82 Overview: SGS Sa
Figure 83 SWOT: SGS Sa
Figure 84 Overview: Syngene International Ltd.
Figure 85 SWOT: Syngene International
Figure 86 Overview: Thermo Fisher Scientific
Figure 87 SWOT: Thermo Fisher Scientific
Figure 88 Overview: Wuxi Apptec Co. Ltd
Figure 89 SWOT: Wuxi Apptec Co. Ltd
Figure 90 Overview: Wuxi Biologics
Figure 91 SWOT: Wuxi Biologics

Note: Product cover images may vary from those shown

Loading
LOADING...

  • 3P Biopharmaceuticals
  • A & G Pharmaceutical Inc (Precision Antibody)
  • Abbvie Inc. (Abbvie Contract Manufacturing)
  • AbSci, LLC
  • Absolute antibody
  • Abzena PLC
  • Adimab, LLC
  • AGC Inc. (AGC Biologics)
  • Agronaut Manufacturing Services
  • Ajinomoto Co. Inc. (Ajinomoto Biopharma services)
  • Albany Molecular Research Inc. (AMRI)
  • Anthem Biosciences Private Limited.
  • Applied StemCell Inc.
  • Avid Bioservices Inc.
  • Axis Biotech Brasil
  • Batavia Biosciences B.V.
  • Binex Co. Ltd.
  • Biodextris
  • BioFactura, Inc
  • Boehringer Ingelheim International GmbH
  • BPS Bioscience, Inc.
  • Catalent Inc.
  • Celonic AG (Glycotope GmbH)
  • Cevec Pharmaceuticals GmbH
  • CEVEC Pharmaceuticals GmbH
  • Charles River Laboratories International Inc.
  • Cognate Bioservices Inc.
  • Creative Biolabs
  • Creative Diagnostics
  • Cytovance Biologics
  • Dyadic International, Inc.
  • EirGenix, Inc.
  • Envigo
  • Eurofins Scientific S.E
  • Evotec
  • Fujifilm Holdings Corporation
  • Fusion Antibodies
  • Genscript Biotech Corporation
  • GVK Biosciences Private Limited
  • Horizon Discovery Ltd.
  • Immunoreagents Inc.
  • Intertek Group plc
  • IQVIA Holdings Inc (Q2 Solutions)
  • JHL biotech Inc.
  • JSR Corporation
  • Kemwell Biopharma
  • Laboratory Corporation of America Holdings
  • Lake Pharma Inc.
  • LFB Biomanufacturing
  • Lonza Group Ltd.
  • Luina Bio Pty Ltd.
  • Merck KGaA (BioReliance)
  • Miltenyi biotec B.V.& Co. KG
  • NeuClone Pty. Ltd.
  • Northway BiotechPharma
  • PanGen Biotech Inc.
  • Premas Biotech Pvt Ltd.
  • ProMab Biotechnologies, Inc
  • Proteogenix
  • Proventus Bio
  • Px'Therapeutics
  • Rentschler Biopharma SE
  • Samsung Biologics Co. Ltd.
  • Sartorious Group
  • SGS SA
  • Sino Biological Inc.
  • Solentim Ltd.
  • Syd labs
  • Syngene International Ltd.
  • The Antibody lab
  • The Menarini Group
  • Therapure Biopharma Inc.
  • Thermo fisher Scientific Inc.
  • Trenzyme GmbH
  • Viva Biotech Ltd.
  • Wacker Chemie AG
  • Waisman clinical biomanufacturing
  • Wuxi Biologics (Cayman) Inc.
Note: Product cover images may vary from those shown
Adroll
adroll